MyAmyloidosisTeam

The Helios-B study is a clinical trial designed to evaluate the long-term safety and efficacy of vutrisiran for patients with hereditary transthyretin-mediated (hATTR) amyloidosis. This study is set to last seven years and will provide more information on the long-term safety and efficacy of the drug. The trial compares Show Full Answer

The Helios-B study is a clinical trial designed to evaluate the long-term safety and efficacy of vutrisiran for patients with hereditary transthyretin-mediated (hATTR) amyloidosis. This study is set to last seven years and will provide more information on the long-term safety and efficacy of the drug. The trial compares vutrisiran to a placebo (saline injection) and aims to gather comprehensive data over this period.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

hATTR Amyloidosis Treatments: Comparing Your Options | MyAmyloidosisTeam

Amvuttra (Vutrisiran) for Amyloidosis | MyAmyloidosisTeam